vidutolimod
vidutolimod: developed by 1 company · 1 clinical trial tracked.
vidutolimod evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect vidutolimod to CMPI; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could vidutolimod → CMPI affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Related indications
anti-PD-1 refractory melanoma, first-line melanoma, advanced head and neck squamous cell carcinoma (HNSCC), cutaneous squamous cell carcinoma, and Merkel cell carcinomaBasal Cell CarcinomaCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaNon-Small Cell Lung CancerTriple Negative Breast Cancer
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CHECKMATE PHARMACEUTICALS, INC. (CMPI) anti-PD-1 refractory melanoma, first-line melanoma, advanced… | Phase 2 |
Clinical Trials (1)
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Primary endpoint: Objective Response Rate (ORR)
Interventionalopen77 targetStarted 2021-11Completion 2024-1024 sites · Australia, United StatesRegeneron Pharmaceuticals
Frequently asked questions
Who is developing vidutolimod?
vidutolimod is being developed by CHECKMATE PHARMACEUTICALS, INC..
How many clinical trials involve vidutolimod?
BioSniper tracks 1 clinical trial involving vidutolimod.